Showing 4191-4200 of 5911 results for "".
- Marinomed Biotech to Launch Carragelose Eye Drops in Europe in 2024https://modernod.com/news/marinomed-biotech-to-launch-carragelose-eye-drops-in-europe-in-2024/2481677/Marinomed Biotech announced it plans to introduce a new Carragelose eye drop product (MAM-1001-3) with an expected market launch in Austria targeted for the first half of 2024. Marinomed said it has started a business development process to identify partners for the marketing of the product
- EyeBio Announces First Patients Dosed in Phase 1b/2 Trial of Restoret in Wet AMD and DMEhttps://modernod.com/news/eyebio-announces-first-patients-dosed-in-phase-1b2-trial-of-restoret-in-wet-amd-and-dme/2481675/Eyebiotech announced the dosing of the first participants in its phase 1b/2 AMARONE (Anti-permeability Mechanism and Age-Related Ocular Neovascularization Evaluation) clinical trial in patients with diabetic macular edema (DME) and wet age-related macular degeneration (AMD). The AMARONE tria
- Zeiss Unveils Disposable Warm Eye Maskshttps://modernod.com/news/zeiss-unveils-disposable-zeiss-warm-eye-masks/2481674/Zeiss announced the release of Zeiss Warm Eye Masks, individually wrapped and disposable masks designed to refresh and soothe dry, tired eyes. The masks use gentle heat to soothe, relax and stimulate the oil glands (meibomian glands) in eyelids. The warmth helps to unbloc
- Senju Pharmaceutical and Novaliq Enter Into License Agreement For NOV03 For the Treatment of Dry Eye Disease in Japanhttps://modernod.com/news/senju-pharmaceutical-and-novaliq-enter-into-license-agreement-for-nov03-for-the-treatment-of-dry-eye-disease-in-japan/2481671/Senju Pharmaceutical and Novaliq have enteed into a license agreement for NOV03 (perfluorohexyloctane ophthalmic solution) for the treatment of dry eye disease in Japan. Financial terms of the deal were not disclosed. Senju Pharmaceutical acquires the rights in Japa
- CORE Publishes Resource on Ectatic Corneal Diseaseshttps://modernod.com/news/core-publishes-resource-on-ectatic-corneal-diseases/2481670/As ectatic corneal diseases—such as keratoconus—pose significant challenges to vision and quality of life, the Centre for Ocular Research & Education (CORE) has dedicated Issue 72 of
- Ocular Therapeutix Announces 12-Month Topline Data from Ongoing Phase 1 Trial Evaluating OTX-TKI for Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-12-month-topline-data-from-ongoing-phase-1-trial-evaluating-otx-tki-for-wet-amd/2481669/Ocular Therapeutix announced 12-month data from its phase 1 US clinical trial evaluating OTX-TKI, the company’s axitinib intravitreal hydrogel implant, for the treatment of wet age-related macular degeneration (AMD). OTX-TKI is also being developed for the treatment of diabetic retinop
- Bausch + Lomb Launches PreserVision AREDS 2 Formula Soft Gels Plus CoQ10 in the United Stateshttps://modernod.com/news/bausch-lomb-launches-preservision-areds-2-formula-soft-gels-plus-coq10-in-the-united-states/2481667/Bausch + Lomb announced the US launch of PreserVision AREDS 2 Formula soft gels plus coenzyme Q10 (CoQ10). Developed as a two-in-one option, Bausch + Lomb says PreserVision AREDS 2 Formula eye vitamins plus CoQ10 is the only eye vitamin that combines the exact nutrient formula
- MediPrint Ophthalmics Announces Results from its SIGHT-2 Phase 2b Group 1 Clinical Studyhttps://modernod.com/news/mediprint-ophthalmics-announces-results-from-its-sight-2-phase-2b-group-1-clinical-study/2481665/MediPrint Ophthalmics announced it has completed its SIGHT-2 dose-finding phase 2b Group 1 (low dose) study for its proprietary drug-eluting contact lens for glaucoma. This is the first of potentially three doses in the second study of its clinical program SIGHT (Sustained Innovati
- Reduction of Eyedrop Volume for Topical Ophthalmic Medications with the Nanodropper Bottle Adaptorhttps://modernod.com/news/reduction-of-eyedrop-volume-for-topical-ophthalmic-medications-with-the-nanodropper-bottle-adaptor/2481663/Nanodropper announced positive results from a research study conducted in collaboration with Leonard Seibold, MD, Professor of Ophthalmology at University of Colorado School of Medicine, which quantified eyedrop volume reduction and bottle life extension with the Nanodropper adaptor compared
- Prevent Blindness Launches Multiple Efforts to Provide Education and Resources on the Effects of Vision Loss and Blindness on Mental Healthhttps://modernod.com/news/prevent-blindness-launches-multiple-efforts-to-provide-education-and-resources-on-the-effects-of-vision-loss-and-blindness-on-mental-health/2481658/Nonprofit group Prevent Blindness is raising awareness on the impact of vision Impairment on mental wellbeing through upcoming focus on Eye Health Summit presentations and web resources. "Because individuals with vision loss can experience a higher prevalence of depres